BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 19147579)

  • 1. Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.
    Hofer MD; Kuefer R; Maier C; Herkommer K; Perner S; Demichelis F; Paiss T; Vogel W; Rubin MA; Hoegel J
    Cancer Res; 2009 Jan; 69(2):640-6. PubMed ID: 19147579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes.
    Luedeke M; Linnert CM; Hofer MD; Surowy HM; Rinckleb AE; Hoegel J; Kuefer R; Rubin MA; Vogel W; Maier C
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3030-5. PubMed ID: 19861517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.
    Demichelis F; Fall K; Perner S; Andrén O; Schmidt F; Setlur SR; Hoshida Y; Mosquera JM; Pawitan Y; Lee C; Adami HO; Mucci LA; Kantoff PW; Andersson SO; Chinnaiyan AM; Johansson JE; Rubin MA
    Oncogene; 2007 Jul; 26(31):4596-9. PubMed ID: 17237811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
    Winnes M; Lissbrant E; Damber JE; Stenman G
    Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer.
    Leinonen KA; Tolonen TT; Bracken H; Stenman UH; Tammela TL; Saramäki OR; Visakorpi T
    Clin Cancer Res; 2010 May; 16(10):2845-51. PubMed ID: 20442300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
    Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
    Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis.
    Rostad K; Hellwinkel OJ; Haukaas SA; Halvorsen OJ; Øyan AM; Haese A; Budäus L; Albrecht H; Akslen LA; Schlomm T; Kalland KH
    APMIS; 2009 Aug; 117(8):575-82. PubMed ID: 19664128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
    Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
    J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.
    Hermans KG; Boormans JL; Gasi D; van Leenders GJ; Jenster G; Verhagen PC; Trapman J
    Clin Cancer Res; 2009 Oct; 15(20):6398-403. PubMed ID: 19825963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.
    Perner S; Mosquera JM; Demichelis F; Hofer MD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; De Marzo AM; Rubin MA
    Am J Surg Pathol; 2007 Jun; 31(6):882-8. PubMed ID: 17527075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
    Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
    Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer.
    Wang J; Cai Y; Ren C; Ittmann M
    Cancer Res; 2006 Sep; 66(17):8347-51. PubMed ID: 16951141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.
    Rajput AB; Miller MA; De Luca A; Boyd N; Leung S; Hurtado-Coll A; Fazli L; Jones EC; Palmer JB; Gleave ME; Cox ME; Huntsman DG
    J Clin Pathol; 2007 Nov; 60(11):1238-43. PubMed ID: 17259299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients.
    Lee K; Chae JY; Kwak C; Ku JH; Moon KC
    Urology; 2010 Nov; 76(5):1268.e7-13. PubMed ID: 20800881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
    Saramäki OR; Harjula AE; Martikainen PM; Vessella RL; Tammela TL; Visakorpi T
    Clin Cancer Res; 2008 Jun; 14(11):3395-400. PubMed ID: 18519769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
    Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
    Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
    Helgeson BE; Tomlins SA; Shah N; Laxman B; Cao Q; Prensner JR; Cao X; Singla N; Montie JE; Varambally S; Mehra R; Chinnaiyan AM
    Cancer Res; 2008 Jan; 68(1):73-80. PubMed ID: 18172298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome linkage screen for prostate cancer susceptibility loci: results from the Mayo Clinic Familial Prostate Cancer Study.
    Cunningham JM; McDonnell SK; Marks A; Hebbring S; Anderson SA; Peterson BJ; Slager S; French A; Blute ML; Schaid DJ; Thibodeau SN;
    Prostate; 2003 Dec; 57(4):335-46. PubMed ID: 14601030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide scan for prostate cancer susceptibility genes in the Johns Hopkins hereditary prostate cancer families.
    Xu J; Gillanders EM; Isaacs SD; Chang BL; Wiley KE; Zheng SL; Jones M; Gildea D; Riedesel E; Albertus J; Freas-Lutz D; Markey C; Meyers DA; Walsh PC; Trent JM; Isaacs WB
    Prostate; 2003 Dec; 57(4):320-5. PubMed ID: 14601028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microdeletion and concurrent translocation associated with a complex TMPRSS2:ERG prostate cancer gene fusion.
    Yoshimoto M; Ludkovski O; Bayani J; Graham C; Zielenska M; Squire JA
    Genes Chromosomes Cancer; 2007 Sep; 46(9):861-3. PubMed ID: 17584912
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.